GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (NAS:CRBP) » Definitions » Cyclically Adjusted FCF per Share

Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Cyclically Adjusted FCF per Share : $-16.90 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Corbus Pharmaceuticals Holdings Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Corbus Pharmaceuticals Holdings's adjusted free cash flow per share for the three months ended in Mar. 2024 was $-0.959. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-16.90 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-16), Corbus Pharmaceuticals Holdings's current stock price is $44.14. Corbus Pharmaceuticals Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $-16.90. Corbus Pharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF of today is .


Corbus Pharmaceuticals Holdings Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings Cyclically Adjusted FCF per Share Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -16.82

Corbus Pharmaceuticals Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -16.88 -16.76 -16.82 -16.90

Competitive Comparison of Corbus Pharmaceuticals Holdings's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corbus Pharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF falls into.



Corbus Pharmaceuticals Holdings Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Corbus Pharmaceuticals Holdings's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.959/129.4194*129.4194
=-0.959

Current CPI (Mar. 2024) = 129.4194.

Corbus Pharmaceuticals Holdings Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.374 100.560 -0.481
201409 -0.672 100.428 -0.866
201412 -1.527 99.070 -1.995
201503 -1.487 99.621 -1.932
201506 0.006 100.684 0.008
201509 -2.147 100.392 -2.768
201512 -0.775 99.792 -1.005
201603 -2.057 100.470 -2.650
201606 -2.050 101.688 -2.609
201609 -2.139 101.861 -2.718
201612 -3.769 101.863 -4.789
201703 -4.318 102.862 -5.433
201706 -3.441 103.349 -4.309
201709 -3.809 104.136 -4.734
201712 -5.398 104.011 -6.717
201803 -1.527 105.290 -1.877
201806 -3.271 106.317 -3.982
201809 -4.695 106.507 -5.705
201812 -7.502 105.998 -9.160
201903 4.982 107.251 6.012
201906 -7.256 108.070 -8.689
201909 -8.483 108.329 -10.135
201912 -11.064 108.420 -13.207
202003 -12.155 108.902 -14.445
202006 -10.809 108.767 -12.861
202009 -10.007 109.815 -11.793
202012 -6.236 109.897 -7.344
202103 -5.624 111.754 -6.513
202106 -4.519 114.631 -5.102
202109 0.205 115.734 0.229
202112 -2.335 117.630 -2.569
202203 -2.549 121.301 -2.720
202206 -2.933 125.017 -3.036
202209 -1.737 125.227 -1.795
202212 -1.787 125.222 -1.847
202303 -3.614 127.348 -3.673
202306 -1.823 128.729 -1.833
202309 -1.622 129.860 -1.617
202312 -1.358 129.419 -1.358
202403 -0.959 129.419 -0.959

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Corbus Pharmaceuticals Holdings  (NAS:CRBP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Corbus Pharmaceuticals Holdings Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
Address
500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.
Executives
Yong Ben director 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Anne Altmeyer director 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Yuval Cohen director, officer: Chief Executive Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Craig Stuart Millian officer: Chief Commercial Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Sean F. Moran officer: Chief Financial Officer 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Rachael Louise Brake officer: Chief Scientific Officer 21 MANCHESTER PLACE, NATICK MA 01760
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Peter Salzmann director 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Barbara White officer: Chief Medical Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Paul Discordia officer: Chief Operating Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
David P Hochman director 15 WESTON HILL RD., RIVERSIDE CT 06878
John Kenneth Jenkins director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Paris Panayiotopoulos director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alan F Holmer director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062

Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Headlines

From GuruFocus